Before clinical application of EGFR–TKIs, the overall survival of NSCLC patients was only approximately a year, as shown in the trials verifying the efficacy of platinum doublets chemotherapy in metastatic NSCLC11. Here, EGFR is linked to non-small cell lung carcinoma.